Cargando…

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity

Interleukin-15 (IL-15) is a potent cytokine that increases CD8(+) T and NK cell numbers and function in experimental models. However, obstacles remain in using IL-15 therapeutically, specifically its low potency and short in vivo half-life. To help overcome this, a new IL-15 superagonist complex com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bailey, Cavan P., Budak-Alpdogan, Tulin, Sauter, Christopher T., Panis, Michelle M., Buyukgoz, Cihangir, Jeng, Emily K., Wong, Hing C., Flomenberg, Neal, Alpdogan, Onder
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546486/ https://www.ncbi.nlm.nih.gov/pubmed/28574833 http://dx.doi.org/10.18632/oncotarget.17875

Ejemplares similares

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
por: Kim, Peter S., et al.
Publicado: (2016)

Promyelocytic Blast Crisis of Chronic Myeloid Leukemia in a Patient Undergoing Therapy with a Tyrosine Kinase Inhibitor
por: Parsi, Meghana, et al.
Publicado: (2020)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation
por: Pan, Jonathan, et al.
Publicado: (2017)

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
por: Wong, Hing C, et al.
Publicado: (2013)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
por: Knudson, Karin M., et al.
Publicado: (2019)

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
por: Rosario, Maximillian, et al.
Publicado: (2014)

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
por: Fousek, Kristen, et al.
Publicado: (2023)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020)

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
por: Knudson, Karin M, et al.
Publicado: (2020)

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
por: Jochems, Caroline, et al.
Publicado: (2018)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study
por: Drusbosky, Leylah, et al.
Publicado: (2020)

Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
por: Chen, Xiaoyue, et al.
Publicado: (2015)

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
por: Elbezanti, Weam Othman, et al.
Publicado: (2023)

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2019)

4308 DEEP-PRIMED IL-15 SUPERAGONIST IMPROVES ANTIVIRAL EFFICACY OF HIV-SPECIFIC CD8(+) T-CELLS IN HUMANIZED MOUSE MODEL
por: McCann, Chase Daniel, et al.
Publicado: (2020)

Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133(+) Tumor-Initiating Cells
por: Medina, Daniel J., et al.
Publicado: (2014)

Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature
por: Gandhi, S., et al.
Publicado: (2020)

Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD(2)-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2
por: Bodden, Malena, et al.
Publicado: (2023)

Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus
por: Tosic, Vesna, et al.
Publicado: (2013)

Assessment of Interleukin-15 (IL-15) Concentration in Children with Idiopathic Nephrotic Syndrome
por: Badeński, Andrzej, et al.
Publicado: (2023)

IL-15 Superagonist Expands mCD8(+ )T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection
por: Patil, Naeem K., et al.
Publicado: (2016)

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2020)

Are there superagonists for calcium-activated potassium channels?
por: Brown, Brandon M., et al.
Publicado: (2017)

Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques
por: McBrien, Julia B., et al.
Publicado: (2020)

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022)

Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2021)

Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases
por: Waldmann, Thomas A
Publicado: (2004)

Interleukin-7 and Interleukin-15 for Cancer
por: Zarogoulidis, Paul, et al.
Publicado: (2014)

Myxoma Virus Expressing a Fusion Protein of Interleukin-15 (IL15) and IL15 Receptor Alpha Has Enhanced Antitumor Activity
por: Tosic, Vesna, et al.
Publicado: (2014)

Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation
por: Swaminathan, Sanjay, et al.
Publicado: (2016)

P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms
por: LIN, SIANG-YO, et al.
Publicado: (2013)

Amlodipine-induced hypersensitivity reaction mimicking CD30(+) mycosis fungoides
por: Gochoco, Ashley, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1d8f5sg25k0e8n90fbpob463v0